Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026949 · ClinicalTrials.gov registry record
Study of Etoposide in Breast Cancer Patients
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 33
- Enrollment target
NCT00026949: Completed study, sponsored by National Cancer Institute (NCI).
NCT00026949 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026949 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This study will examine how the body handles etoposide, a drug used to treat breast cancer. The knowledge gained may lead to more effective use of the drug with fewer side effects in the future. Breast cancer patients who are receiving etoposide as part of their treatment may participate in this study. Patients will have 18 blood samples (about a teaspoon or less each) drawn over a 72-hour period during and after their infusion of etoposide. The initial blood samples cannot be taken from the same intravenous line (small tube placed in a vein) used to deliver the etoposide, so a second line may have to be placed temporarily to obtain these samples.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 1999-08 |
| Est. Completion | 2004-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026949
The ClinicalTrials.gov registry entry for NCT00026949 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00026949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026949 about?
NCT00026949 is a clinical study titled "Study of Etoposide in Breast Cancer Patients". This study will examine how the body handles etoposide, a drug used to treat breast cancer. The knowledge gained may lead to more effective use of the drug with fewer side effects in the future. Breast cancer patients who are receiving etoposide as part of their treatment may participate in this st...
What is the current status of trial NCT00026949?
This trial is currently completed. The enrollment target is 33 participants. The study started on 1999-08. Estimated completion is 2004-08.
Who is sponsoring clinical trial NCT00026949?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.